*Clinical Research Division, Fred Hutchinson Cancer Center
†Department of Laboratory Medicine and Pathology
‡Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA
S.S.T. and M.T. contributed equally.
This work was supported by a Technology Development Grant from the Washington Research Foundation to SST, a Department of Defense Kidney Cancer Research Program Translational Research Partnership Award (KC180135 to S.A. and S.S.T.), NIH/NCI Cancer Center Support Grant P30 CA015704, and philanthropic gifts in support of kidney cancer research to the Fred Hutchinson Cancer Center.
S.S.T., Y.X., E.H.W., and M.T.: designed the study; C.P.M.: performed the gene editing and T-cell cytotoxicity; F.S. and M.T.: compiled the tissue microarrays and performed the IHC; M.T.: performed the scoring of IHC and RNA in situ hybridization; M.T. and S.A.: provided expert pathology interpretation; S.A.: performed the RNA in situ hybridization; Y.X.: performed the Kaplan-Meier analysis; C.P.M. and M.T.: performed the data analysis and prepared the figures; C.P.M.: wrote the manuscript; C.P.M., F.S., S.A., Y.X., E.H.W., S.S.T., and M.T.: interpreted the data and reviewed and revised the manuscript.
The authors declare no conflict of interest.
Reprints: Christopher P. Miller, PhD, Clinical Research Division, Fred Hutchinson Cancer Center, Mailstop: S3-204, 1100 Fairview Avenue NE, Seattle, WA 98109 (e-mail: [email protected]).
Supplemental Digital Content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's website, www.appliedimmunohist.com.
